Building An Evidence Base For Funding Evidence-based Medicine
Funder
National Health and Medical Research Council
Funding Amount
$316,338.00
Summary
Funding schemes should be subject to the same scientific scrutiny as the proposals they scrutinize. If funding schemes could be improved, and higher quality proposals funded more reliably, then evidence-based medicine throughout Australia could be improved. Current evidence shows a concerning variability in funding decisions. We will examine the costs and reliability of the Project Grant scheme and two cheaper alternatives. Any savings we find could be re-invested back into medical research.
Can Shoe Inserts Reduce The Burden Of Kneecap Osteoarthritis?
Funder
National Health and Medical Research Council
Funding Amount
$644,550.00
Summary
Kneecap arthritis is a leading cause of pain, disability and health expenditure in the Australian community. ‘Off-the-shelf’ shoe inserts are simple, low-cost devices that can reduce kneecap pain in young adults, and are accessible to all Australians. This project investigates whether ‘off-the-shelf’ shoe inserts improve pain in older adults with kneecap arthritis over 12 months, and evaluates the relationship between cost and patient benefits.
Preventing Hospital Readmission In A Regional Australian Hospital Setting
Funder
National Health and Medical Research Council
Funding Amount
$565,695.00
Summary
Hospitals face high levels of emergency presentations and demand for inpatient care particularly for Aboriginal Australian people from remote communities. Readmissions lead to overcrowded emergency departments and poorer patient outcomes. We will evaluate the efficacy of a multidimensional case-based management intervention linking hospital and primary health in a regional Australian hospital with the aim of reducing hospital readmission and improving patient outcomes.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.
The Tasmanian Healthy Brain Project: A Longitudinal Intervention Study To Reduce The Risk Of Ageing-related Cognitive Decline And Dementia
Funder
National Health and Medical Research Council
Funding Amount
$878,792.00
Summary
It has been proposed that engagement in purposeful complex mental stimulation provides protection against dementia. The Tasmanian Healthy Brain Project (THBP) is a unique, large-scale prospective trial that examines whether university-level study in older adult population reduces ageing-related cognitive decline and risk of dementia. This project will also examine how an individual’s genetic profile may influence the potential benefits of complex mental stimulation as well as risk of dementia.